These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16862858)

  • 1. [Hepatotoxicity of coinfected patients].
    Bessone F; Belloso W; Schroder T
    Acta Gastroenterol Latinoam; 2006 Jun; 36 Suppl 1():S43-5; discussion S74-82. PubMed ID: 16862858
    [No Abstract]   [Full Text] [Related]  

  • 2. Elevated liver enzymes in HIV monoinfected patients on HIV therapy: what are the implications?
    Ingiliz P; Benhamou Y
    J HIV Ther; 2009 Mar; 14(1):3-7. PubMed ID: 19731558
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade.
    Sauleda S; Martorell M; Esteban JI; Tural C; Ruiz I; Puig L; Esteban R; Guardia J; Vargas V
    Haemophilia; 2006 May; 12(3):228-36. PubMed ID: 16643206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV infection, antiretroviral therapy, and hepatic function. Emerging epidemiological, pathogenetic, and clinical issues, and their consequences on disease management.
    Manfredi R
    AIDS; 2003 Oct; 17(15):2253-6. PubMed ID: 14523283
    [No Abstract]   [Full Text] [Related]  

  • 5. Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Liver Pathology.
    Sonderup MW; Wainwright HC
    Gastroenterol Clin North Am; 2017 Jun; 46(2):327-343. PubMed ID: 28506368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De-"Liver"-ing HIV/hepatitis C virus-coinfected patients from antiretroviral hepatotoxicity.
    Cooper CL
    J Infect Dis; 2007 Sep; 196(5):656-8. PubMed ID: 17674305
    [No Abstract]   [Full Text] [Related]  

  • 7. Potential adverse effects and inferior efficacy in ARV treatment.
    Graves D; Cocohoba J; Gruta C; Goldschmidt R
    J Natl Med Assoc; 2004 May; 96(5):692-3; author reply 693. PubMed ID: 15160990
    [No Abstract]   [Full Text] [Related]  

  • 8. HIV/HCV co-infection: clinical and therapeutic challenges.
    Ensoli F; Sirianni MC
    AIDS; 2002 Jul; 16(10):1419-20. PubMed ID: 12131219
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
    Labarga P; Soriano V; Vispo ME; Pinilla J; Martin-Carbonero L; Castellares C; Casado R; Maida I; Garcia-Gasco P; Barreiro P
    J Infect Dis; 2007 Sep; 196(5):670-6. PubMed ID: 17674307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-term consequences of antiretroviral therapy: a review.
    Boyd M; Reiss P
    J HIV Ther; 2006 Jun; 11(2):26-35. PubMed ID: 16981593
    [No Abstract]   [Full Text] [Related]  

  • 12. Recurrent NNRTI-induced hepatotoxicity in an HIV-HCV-coinfected patient.
    Piroth L; Grappin M; Sgro C; Buisson M; Duong M; Chavanet P
    Ann Pharmacother; 2000 Apr; 34(4):534-5. PubMed ID: 10772444
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimal treatment of nevirapine-associated hepatotoxicity remains uncertain.
    Bundow D; Rosoff L; Aboulafia DM
    AIDS Read; 2001 Nov; 11(11):577-80. PubMed ID: 11789021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral drugs and liver injury.
    Soriano V; Puoti M; Garcia-Gascó P; Rockstroh JK; Benhamou Y; Barreiro P; McGovern B
    AIDS; 2008 Jan; 22(1):1-13. PubMed ID: 18090386
    [No Abstract]   [Full Text] [Related]  

  • 15. Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?
    Sandrine PF; Sylvie A; André E; Abdoulaye D; Bernard L; André C
    AIDS; 2007 Jul; 21(11):1498-9. PubMed ID: 17589205
    [No Abstract]   [Full Text] [Related]  

  • 16. HAART-associated body habitus and metabolic changes, Part 1.
    Liss M; Boyle BA
    AIDS Read; 2000 Nov; 10(11):622, 629-31. PubMed ID: 11186180
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiretroviral therapy-related hepatotoxicity: predictors and clinical management.
    Dore G
    J HIV Ther; 2003 Nov; 8(4):96-100. PubMed ID: 14671507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risks of antiretroviral therapy.
    Stein JH
    N Engl J Med; 2007 Apr; 356(17):1773-5. PubMed ID: 17460232
    [No Abstract]   [Full Text] [Related]  

  • 20. Warfarin-antiretroviral interactions.
    Liedtke MD; Rathbun RC
    Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.